Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine.
We assessed the occurrence of oculo-respiratory syndrome (ORS) following two influenza vaccines: Fluviral (Shire Biologics) or Vaxigrip (Aventis Pasteur). ORS was identified amongst 5.3 and 4.6% of recipients, respectively (P=0.54). With both vaccines, the risk of ORS was much greater in individuals who had ORS the previous year (2000) than in those without such history. In multivariate analysis, the odds ratio for ORS for patients with a prior history of ORS varied between 9.4 and 9.6 (P<0.001) whereas that comparing Fluviral and Vaxigrip varied between 1.5 and 1.9 (P=0.02-0.05). ORS is an adverse event that is present with more than one vaccine and may be present with any influenza vaccines to a greater or lesser degree.
De Serres
Gaston
G
Direction de la santé publique de Québec, Que, Québec, Canada G1E 7G9. gaston.deserres@ssss.gouv.qc.ca
Boulianne
Nicole
N
Duval
Bernard
B
Rochette
Louis
L
Grenier
Jean Luc
JL
Roussel
Renée
R
Donaldson
Danièle
D
Tremblay
Michèle
M
Toth
Eveline
E
Ménard
Suzanne
S
Landry
Monique
M
Robert
Yves
Y
D000328:Adult; D015331:Cohort Studies; D005128:Eye Diseases / Q000209:etiology*; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011792:Quebec; D012140:Respiratory Tract Diseases / Q000209:etiology*; D012189:Retrospective Studies; D015164:Vaccines, Inactivated / Q000009:adverse effects
D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; C478242:vaxigrip